EDP1908 / Evelo Biosci - LARVOL DELTA

[VIRTUAL] Oral delivery of a microbial extracellular vesicle induces potent anti-tumor immunity in mice (IMMUNOLOGY 2021) - "These data point to oral EVs as a new class of immunotherapeutic drugs that harness the biology of the small intestinal axis, acting locally on host cells in the gut to control distal immune responses within the TME. EDP1908 is in preclinical development for the treatment of cancer."

Preclinical • Oncology • CD4 • CD8 • IFNG

[VIRTUAL] Oral delivery of a microbial extracellular vesicle induces potent anti-tumor immunity in mice (IMMUNOLOGY 2021) - "These data point to oral EVs as a new class of immunotherapeutic drugs that harness the biology of the small intestinal axis, acting locally on host cells in the gut to control distal immune responses within the TME. EDP1908 is in preclinical development for the treatment of cancer."

Preclinical • Oncology • CD4 • CD8 • IFNG

Evelo Biosciences Reports First Quarter 2021 Financial Results and Business Highlights (GlobeNewswire) - "Upcoming Key Milestones: EDP1908...Initiation of clinical development in 2022."

Clinical • Oncology

Evelo Biosciences Announces Fourth Quarter and Full Year 2020 Financial Results and Business Highlights (GlobeNewswire) - “Upcoming Key Milestones: EDP1908 – Oncology - Initiation of clinical development in 2022.”

Pipeline update • Oncology

Evelo Biosciences Announces Pricing of Public Offering of Common Stock (GlobeNewswire) - "Evelo Biosciences, Inc....announced the pricing of an underwritten public offering of 4,500,000 shares of its common stock, at a public offering price of $15.00 per share...Evelo intends to use the net proceeds from the offering, in addition to its existing cash resources, for the following purposes: (i) continue the development of EDP1815 in a Phase 2 trial in psoriasis and initiate a Phase 2 trial of EDP1815 in atopic dermatitis; (ii) prepare to advance EDP1815 in multiple Phase 3 trials in psoriasis and atopic dermatitis...(iii) continue the Phase 2 and Phase 2/3 clinical trials of EDP1815 for the treatment of hyperinflammation caused by SARs-CoV-2; (iv) advance EDP1867 in a Phase 1b trial in atopic dermatitis; (v) progress its first bacterial extracellular vesicle product candidates into the clinic, including EDP2939 for inflammation and EDP1908 for oncology."

Financing • Atopic Dermatitis • Immunology • Infectious Disease • Inflammation • Novel Coronavirus Disease • Oncology • Psoriasis

Evelo Biosciences Expands Clinical Programs and Provides 2021 Guidance on Key Milestones (GlobeNewswire) - “EDP1908 – Oncology Initiation of Phase 1 trial in 2022.”

New P1 trial • Oncology

[VIRTUAL] Oral delivery of a microbial extracellular vesicle induces potent anti-tumor immunity in mice (SITC 2020) - "Methods EDP1908 is a preparation of extracellular vesicles produced by a gram-stain negative strain of bacterium of the Oscillospiraceae family isolated from a human donor...Ethics Approval Preclinical murine studies were conducted under the approval of the Avastus Preclinical Services’ Ethics Board. Human in vitro samples were attained by approval of the IntegReview Ethics Board; informed consent was obtained from all subjects."

Oncology • CD8 • IFNG

[VIRTUAL] Oral delivery of a microbial extracellular vesicle induces potent anti-tumor immunity in mice (SITC 2020) - "Methods EDP1908 is a preparation of extracellular vesicles produced by a gram-stain negative strain of bacterium of the Oscillospiraceae family isolated from a human donor...Ethics Approval Preclinical murine studies were conducted under the approval of the Avastus Preclinical Services’ Ethics Board. Human in vitro samples were attained by approval of the IntegReview Ethics Board; informed consent was obtained from all subjects."

Oncology • CD8 • IFNG

Evelo Biosciences Presents New Preclinical Data for Anti-Tumor Effects of Orally Delivered Microbial Extracellular Vesicles at the SITC 35th Anniversary Annual Meeting (GlobeNewswire) - "In the preclinical study presented at SITC, tumor-bearing mice were treated with ascending doses of either oral EDP1908 or the parental microbial strain of EDP1908, or with anti-PD-1. Treatment with EDP1908 resulted in superior tumor growth control versus either the parent microbial strain or anti-PD-1 therapy, with a dose-dependent reduction of tumor growth. The effects were also at least comparable to those reported in the literature for intra-tumoral immune stimulators."

Preclinical • Oncology